Company intelligence / Profile preview
Mebiopharm
Minato, Tokyo, Japanmebiopharm.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
01
Overview
Mebiopharm develops novel anticancer drugs using proprietary liposome-based drug delivery systems. Their lead assets include a transferrin-targeted, methotrexate-loaded liposomal product licensed to Fuan Pharmaceutical for China, a Nek2 siRNA nucleic acid drug under academic collaboration with Nagoya University, and nanoparticle ultrasound contrast agents. The company has ongoing partnerships with major pharma companies like Merck and academic institutions such as Osaka University. At least one program has reached Phase 2 trials in Europe; others are at various stages from preclinical to early clinical development.
- Therapeutic areas
- Oncology
- Modalities
- Liposome-based drug delivery therapyNucleic acid (siRNA) therapySmall moleculeNanoparticle-based contrast agent
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →03
Partnerships
Merck (technology evaluation agreement)Fuan Pharmaceutical Group Co., Ltd. (China licensee)Nagoya University Surgical Oncology DepartmentOsaka University Research Institute for Microbial Diseases
Beyond the preview
Go deeper on Mebiopharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mebiopharm.